Comparison of Doxycycline, Minocycline, Doxycycline plus Albendazole and Albendazole Alone in Their Efficacy against Onchocerciasis in a Randomized, Open-Label, Pilot Trial.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Albendazole/*administration & dosage ; Anthelmintics/*administration & dosage ; Doxycycline/*administration & dosage ; Minocycline/*administration & dosage ; Onchocerciasis/*drug therapy; Adolescent ; Adult ; Animals ; Drug Therapy, Combination ; Female ; Ghana ; Humans ; Male ; Middle Aged ; Onchocerca volvulus/drug effects ; Onchocerca volvulus/genetics ; Onchocerca volvulus/isolation & purification ; Onchocerca volvulus/physiology ; Onchocerciasis/parasitology ; Pilot Projects ; Treatment Outcome ; Young Adult

The search for new macrofilaricidal drugs against onchocerciasis that can be administered in shorter regimens than required for doxycycline (DOX, 200mg/d given for 4-6 weeks), identified minocycline (MIN) with superior efficacy to DOX. Further reduction in the treatment regimen may be achieved with co-administration with standard anti-filarial drugs. Therefore a randomized, open-label, pilot trial was carried out in an area in Ghana endemic for onchocerciasis, comprising 5 different regimens: the standard regimen DOX 200mg/d for 4 weeks (DOX 4w, N = 33), the experimental regimens MIN 200mg/d for 3 weeks (MIN 3w; N = 30), DOX 200mg/d for 3 weeks plus albendazole (ALB) 800mg/d for 3 days (DOX 3w + ALB 3d, N = 32), DOX 200mg/d for 3 weeks (DOX 3w, N = 31) and ALB 800mg for 3 days (ALB 3d, N = 30). Out of 158 randomized participants, 116 (74.4%) were present for the follow-up at 6 months of whom 99 participants (63.5%) followed the treatment per protocol and underwent surgery. Histological analysis of the adult worms in the extirpated nodules revealed absence of Wolbachia in 98.8% (DOX 4w), 81.4% (DOX 3w + ALB 3d), 72.7% (MIN 3w), 64.1% (DOX 3w) and 35.2% (ALB 3d) of the female worms. All 4 treatment regimens showed superiority to ALB 3d (p < 0.001, p < 0.001, p = 0.002, p = 0.008, respectively), which was confirmed by real-time PCR. Additionally, DOX 4w showed superiority to all other treatment arms. Furthermore DOX 4w and DOX 3w + ALB 3d showed a higher amount of female worms with degenerated embryogenesis compared to ALB 3d (p = 0.028, p = 0.042, respectively). These results confirm earlier studies that DOX 4w is sufficient for Wolbachia depletion and the desired parasitological effects. The data further suggest that there is an additive effect of ALB (3 days) on top of that of DOX alone, and that MIN shows a trend for stronger potency than DOX. These latter two results are preliminary and need confirmation in a fully randomized controlled phase 2 trial.
Trial Registration: ClinicalTrials.gov #06010453.
Competing Interests: The author has declared that no competing interests exist.

Lancet. 2001 May 5;357(9266):1415-6. (PMID: 11356444)
PLoS Negl Trop Dis. 2011 Mar 29;5(3):e998. (PMID: 21468315)
Lancet. 2000 Apr 8;355(9211):1242-3. (PMID: 10770311)
Parasit Vectors. 2015 Oct 22;8:552. (PMID: 26489937)
Clin Infect Dis. 2014 Oct;59(7):923-32. (PMID: 24944228)
Microbes Infect. 2003 Apr;5(4):261-73. (PMID: 12706439)
Parasitol Res. 2009 Dec;106(1):23-31. (PMID: 19756742)
Lancet. 2007 Jun 16;369(9578):2021-2029. (PMID: 17574093)
Am J Trop Med Hyg. 2009 Oct;81(4):702-11. (PMID: 19815891)
Trop Med Int Health. 2000 Apr;5(4):275-9. (PMID: 10810023)
Clin Infect Dis. 2015 Apr 15;60(8):1199-207. (PMID: 25537873)
PLoS Negl Trop Dis. 2013;7(1):e2032. (PMID: 23383355)
PLoS One. 2014 Dec 29;9(12):e115886. (PMID: 25545677)
PLoS Pathog. 2006 Sep;2(9):e92. (PMID: 17044733)
Med Microbiol Immunol. 2003 Nov;192(4):211-6. (PMID: 12684759)
Trop Med Parasitol. 1991 Dec;42(4):356-60. (PMID: 1796233)
Filaria J. 2005 Mar 23;4(1):1. (PMID: 15788103)
Clin Infect Dis. 2012 Sep;55(5):621-30. (PMID: 22610930)
Parasitol Res. 2015 Mar;114(3):1129-37. (PMID: 25592754)
Clin Infect Dis. 2008 May 1;46(9):1385-93. (PMID: 18419441)
Infect Dis Poverty. 2016 Jun 27;5(1):66. (PMID: 27349645)
Trop Med Int Health. 2007 Dec;12(12):1433-41. (PMID: 18076549)
Parasitology. 2014 Jan;141(1):119-27. (PMID: 23866958)
Ann Trop Med Parasitol. 1985 Feb;79(1):63-78. (PMID: 3838638)
Int J Parasitol. 2008 Jul;38(8-9):981-7. (PMID: 18282572)
PLoS Negl Trop Dis. 2010 Apr 13;4(4):e660. (PMID: 20405054)
Parasitol Res. 2009 Jan;104(2):437-47. (PMID: 18850111)
Clin Infect Dis. 2016 Jun 1;62(11):1338-1347. (PMID: 27001801)
Proc Biol Sci. 2000 Jun 7;267(1448):1063-9. (PMID: 10885510)
Trans R Soc Trop Med Hyg. 2008 Feb;102(2):148-54. (PMID: 18082234)
Wkly Epidemiol Rec. 2010 Jan 22;85(4):23-8. (PMID: 20095110)
Lancet. 2005 Jun 18-24;365(9477):2116-21. (PMID: 15964448)
Med Microbiol Immunol. 2008 Sep;197(3):295-311. (PMID: 17999080)
Trends Parasitol. 2007 Jun;23(6):237-8. (PMID: 17459773)
Filaria J. 2006 Mar 24;5:4. (PMID: 16563157)
Int J Parasitol Drugs Drug Resist. 2014 Sep 16;4(3):278-86. (PMID: 25516838)
Wkly Epidemiol Rec. 2014 Apr 11;89(15):153-60. (PMID: 24754045)
Parasitol Res. 2009 Nov;105(6):1531-8. (PMID: 19784672)
PLoS Negl Trop Dis. 2011 Jun;5(6):e1210. (PMID: 21738809)
Curr Opin Infect Dis. 2008 Dec;21(6):673-81. (PMID: 18978537)
Trop Med Parasitol. 1994 Sep;45(3):203-8. (PMID: 7899788)
Clin Infect Dis. 2015 Aug 15;61(4):517-26. (PMID: 25948064)
PLoS Negl Trop Dis. 2012;6(4):e1611. (PMID: 22509424)

ISRCTN ISRCTN06010453

0 (Anthelmintics)
F4216019LN (Albendazole)
FYY3R43WGO (Minocycline)
N12000U13O (Doxycycline)

Date Created: 20170106 Date Completed: 20170731 Latest Revision: 20231112

20240104

PMC5215804

10.1371/journal.pntd.0005156

28056021